logo

For the Inventor, By the Inventor

Needham, MA, United States of America

Avant Immunotherapeutics, Inc.


USPTO Granted Patents = 20

% Expired Patents = 20.0


Forward Citations = 340

Loading Chart...
Loading Chart...

41 inventors (with patents filed for the assignee):

goldMedal Lawrence J Thomas (4 out of 12 patents)

silverMedal Charles William Rittershaus (4 out of 23 patents)

bronzeMedal Henry C Marsh (3 out of 17 patents)

4.  Sharon A Jenkins (3 out of 6 patents)

5.  Lloyd B Klickstein (2 out of 13 patents)

6.  Michael F Concino (2 out of 27 patents)

7.  Roy Curtiss, Iii (2 out of 54 patents)

8.  Steven A Tinge (2 out of 4 patents)

9.  Douglas T Fearon (2 out of 7 patents)

10.  Gerald R Carson (2 out of 6 patents)

11.  Savvas C Makrides (2 out of 7 patents)

12.  Winnie W Wong (2 out of 6 patents)

13.  Stephen H Ip (2 out of 28 patents)

14.  Lendon G Payne (2 out of 8 patents)

15.  Victor Bronshtein (1 out of 13 patents)


20 patents:

1. 7341860 - Regulated antigen delivery system (RADS) (2008-03-11),
2. 7078036 - Modulation of cholesteryl ester transfer protein (CETP) activity (2006-07-18),
3. 7074407 - Method for increasing HDL cholesterol level (2006-07-11),
4. 6884866 - Bulk drying and the effects of inducing bubble nucleation (2005-04-26),
5. 6846808 - Plasmid-based vaccine for treating atherosclerosis (2005-01-25),
6. 6841373 - Herpes virus complementing cell line (2005-01-11),
7. 6780405 - Regulated antigen delivery system (RADS) (2004-08-24),
8. 6555113 - Modulation of cholesteryl ester transfer protein (CETP) activity (2003-04-29),
9. 6410022 - Modulation of cholesteryl ester transfer protein (CETP) activity (2002-06-25),
10. 6376235 - IVI-2, IVI-3 and IVI-4 loci of Enterococcus faecalis polynucleotide, polypeptides and method of use therefor (2002-04-23),
11. 6316604 - Human C3b/C4b receptor (CR1) (2001-11-13),
12. 6284533 - Plasmid-based vaccine for treating atherosclerosis (2001-09-04),
13. 6261573 - Immunoadjuvants (2001-07-17),
14. 6207171 - Polyphosphazene microspheres (2001-03-27),
15. 6193979 - Compositions comprising complement receptor type 1 molecules having carbohydrate structures that are selectin ligands (2001-02-27),
Company Overview
Avant Immunotherapeutics, Inc. is a biotechnology company based in Needham, Massachusetts, specializing in the development of innovative immunotherapies. The organization focuses on harnessing the immune system to create treatments for various diseases, particularly in the fields of oncology and infectious diseases. Avant Immunotherapeutics is dedicated to advancing its research and technology to improve patient outcomes through targeted therapies that leverage the body's natural defenses.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

20 Patents

#7 in Needham, MA

#985 in Massachusetts

#16,395 in US

#31,264 in the World

Needham, MA (US)
Needham, MA, United States of America

Avant Immunotherapeutics, Inc.

Forward Citations = 340

41 inventors:

goldMedal Lawrence J Thomas (4 out of 12 patents)

silverMedal Charles William Rittershaus (4 out of 23 patents)

bronzeMedal Henry C Marsh (3 out of 17 patents)

4.  Sharon A Jenkins (3 out of 6 patents)

5.  Lloyd B Klickstein (2 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Avant Immunotherapeutics, Inc.. Retrieved from https://idiyas.com/company/avant-immunotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…